BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 2013;28:155-8. [PMID: 22956028 DOI: 10.1007/s00467-012-2296-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Hu H, Nagra A, Haq MR, Gilbert RD. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 2014;29:1103-6. [DOI: 10.1007/s00467-013-2709-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
2 Joseph C, Gattineni J. Proteinuria and hematuria in the neonate. Curr Opin Pediatr 2016;28:202-8. [PMID: 26845146 DOI: 10.1097/MOP.0000000000000323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kelen D, Chiodini B, Godart V, Adams B, Stordeur P, Ismaili K. Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab. Front Pediatr 2020;8:579607. [PMID: 33681093 DOI: 10.3389/fped.2020.579607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
5 Saikia B, Vashisht N, Gupta N, Sharma A. Exchange transfusion for neonate with haemolytic uremic syndrome. Springerplus 2016;5:52. [PMID: 26835232 DOI: 10.1186/s40064-016-1667-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
8 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
10 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
11 Anastaze Stelle K, Gonzalez E, Wilhelm-Bals A, Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Arch Pediatr 2016;23:283-6. [PMID: 26775886 DOI: 10.1016/j.arcped.2015.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Szarvas N, Szilágyi Á, Tasic V, Nushi-Stavileci V, Sofijanova A, Gucev Z, Szabó M, Szabó A, Szeifert L, Reusz G, Rusai K, Arbeiter K, Müller T, Prohászka Z. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. Ital J Pediatr 2014;40:101. [PMID: 25496981 DOI: 10.1186/s13052-014-0101-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
13 Jernigan SM. Hematuria in the newborn. Clin Perinatol 2014;41:591-603. [PMID: 25155729 DOI: 10.1016/j.clp.2014.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Çakar N, Ozcakar Z, Ozaltin F, Koyun M, Celikel acar B, Bahat E, Gulhan B, Korkmaz E, Yurt A, Yılmaz S, Soylemezoglu O, Yalcinkaya F. Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years. Nephron 2018;139:211-8. [DOI: 10.1159/000487609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
15 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
16 Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:265-72. [DOI: 10.1007/s10157-015-1142-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
17 Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64:633-737. [PMID: 24656451 DOI: 10.1053/j.ajkd.2014.01.434] [Cited by in Crossref: 132] [Cited by in F6Publishing: 106] [Article Influence: 16.5] [Reference Citation Analysis]
18 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Gomes SM, Teixeira RP, Rocha G, Soares P, Guimaraes H, Santos P, Jardim J, Barreira JL, Pinto H. Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era. AJP Rep 2021;11:e95-8. [PMID: 34178424 DOI: 10.1055/s-0041-1731057] [Reference Citation Analysis]
20 Vidal E, Garzotto F, Parolin M, Manenti C, Zanin A, Bellettato M, Remuzzi G, Goldstein SL, Murer L, Ronco C. Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. Blood Purif 2017;44:100-5. [DOI: 10.1159/000470827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
21 Rheault MN. Nephrotic and nephritic syndrome in the newborn. Clin Perinatol 2014;41:605-18. [PMID: 25155730 DOI: 10.1016/j.clp.2014.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
22 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
23 Michaux K, Bacchetta J, Javouhey E, Cochat P, Frémaux-Bacchi V, Sellier-Leclerc AL. Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 2014;29:2415-9. [PMID: 25149852 DOI: 10.1007/s00467-014-2933-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
24 Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab. Clin Nephrol 2015;84:181-5. [PMID: 25816809 DOI: 10.5414/CN108532] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
25 Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatr Nephrol 2013;28:1315-8. [DOI: 10.1007/s00467-013-2492-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]